JP7633725B2 - マイナス鎖ｒｎａウイルスベクターの製造方法および製造されたマイナス鎖ｒｎａウイルスベクター - Google Patents
マイナス鎖ｒｎａウイルスベクターの製造方法および製造されたマイナス鎖ｒｎａウイルスベクター Download PDFInfo
- Publication number
- JP7633725B2 JP7633725B2 JP2023532022A JP2023532022A JP7633725B2 JP 7633725 B2 JP7633725 B2 JP 7633725B2 JP 2023532022 A JP2023532022 A JP 2023532022A JP 2023532022 A JP2023532022 A JP 2023532022A JP 7633725 B2 JP7633725 B2 JP 7633725B2
- Authority
- JP
- Japan
- Prior art keywords
- pkr
- rna
- virus
- sequence
- vai
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000013603 viral vector Substances 0.000 title claims description 84
- 238000004519 manufacturing process Methods 0.000 title claims description 17
- 101710089751 Interferon-induced, double-stranded RNA-activated protein kinase Proteins 0.000 claims description 249
- 102100034170 Interferon-induced, double-stranded RNA-activated protein kinase Human genes 0.000 claims description 249
- 210000004027 cell Anatomy 0.000 claims description 235
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 222
- 241000711408 Murine respirovirus Species 0.000 claims description 153
- 230000002401 inhibitory effect Effects 0.000 claims description 99
- 108090000623 proteins and genes Proteins 0.000 claims description 89
- 241001493065 dsRNA viruses Species 0.000 claims description 78
- 238000004806 packaging method and process Methods 0.000 claims description 75
- 241000700605 Viruses Species 0.000 claims description 73
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 68
- 238000000034 method Methods 0.000 claims description 58
- 230000003612 virological effect Effects 0.000 claims description 57
- 239000013598 vector Substances 0.000 claims description 56
- 108020004414 DNA Proteins 0.000 claims description 53
- 239000003112 inhibitor Substances 0.000 claims description 47
- 239000000203 mixture Substances 0.000 claims description 40
- 230000014509 gene expression Effects 0.000 claims description 36
- 239000013604 expression vector Substances 0.000 claims description 25
- 101800001014 Non-structural protein 5A Proteins 0.000 claims description 23
- 210000003501 vero cell Anatomy 0.000 claims description 18
- 230000001105 regulatory effect Effects 0.000 claims description 17
- 239000003795 chemical substances by application Substances 0.000 claims description 15
- 102000004169 proteins and genes Human genes 0.000 claims description 15
- 241000700584 Simplexvirus Species 0.000 claims description 14
- 241000701161 unidentified adenovirus Species 0.000 claims description 13
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 12
- 241000700618 Vaccinia virus Species 0.000 claims description 12
- 108091034120 Epstein–Barr virus-encoded small RNA Proteins 0.000 claims description 10
- 241000711549 Hepacivirus C Species 0.000 claims description 8
- 101100508081 Human herpesvirus 1 (strain 17) ICP34.5 gene Proteins 0.000 claims description 8
- 101150027249 RL1 gene Proteins 0.000 claims description 8
- 108020001507 fusion proteins Proteins 0.000 claims description 8
- 102000037865 fusion proteins Human genes 0.000 claims description 8
- 241000702263 Reovirus sp. Species 0.000 claims description 7
- 241000712461 unidentified influenza virus Species 0.000 claims description 7
- 238000006467 substitution reaction Methods 0.000 claims description 6
- 108020005345 3' Untranslated Regions Proteins 0.000 claims description 4
- 241000991587 Enterovirus C Species 0.000 claims description 3
- 239000013612 plasmid Substances 0.000 description 95
- 102000039446 nucleic acids Human genes 0.000 description 70
- 108020004707 nucleic acids Proteins 0.000 description 70
- 150000007523 nucleic acids Chemical class 0.000 description 70
- 108090000765 processed proteins & peptides Proteins 0.000 description 48
- 108090000994 Catalytic RNA Proteins 0.000 description 33
- 102000053642 Catalytic RNA Human genes 0.000 description 33
- 108091092562 ribozyme Proteins 0.000 description 33
- 241000282693 Cercopithecidae Species 0.000 description 28
- 101000926535 Homo sapiens Interferon-induced, double-stranded RNA-activated protein kinase Proteins 0.000 description 28
- 102000044003 human EIF2AK2 Human genes 0.000 description 27
- 208000015181 infectious disease Diseases 0.000 description 26
- 239000012634 fragment Substances 0.000 description 25
- 238000002474 experimental method Methods 0.000 description 21
- 239000002245 particle Substances 0.000 description 21
- 150000001413 amino acids Chemical class 0.000 description 19
- 108090001102 Hammerhead ribozyme Proteins 0.000 description 18
- 230000002458 infectious effect Effects 0.000 description 18
- 108091080980 Hepatitis delta virus ribozyme Proteins 0.000 description 17
- 230000000694 effects Effects 0.000 description 17
- 101150034814 F gene Proteins 0.000 description 15
- 229910052757 nitrogen Inorganic materials 0.000 description 15
- 241000711975 Vesicular stomatitis virus Species 0.000 description 13
- 241000894007 species Species 0.000 description 12
- 210000004899 c-terminal region Anatomy 0.000 description 11
- 101150062031 L gene Proteins 0.000 description 10
- 230000001939 inductive effect Effects 0.000 description 10
- 125000003275 alpha amino acid group Chemical group 0.000 description 8
- 230000004927 fusion Effects 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 230000035755 proliferation Effects 0.000 description 8
- 101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 description 7
- 101000611553 Homo sapiens DNA primase large subunit Proteins 0.000 description 7
- 101000976215 Homo sapiens Probable ribonuclease ZC3H12D Proteins 0.000 description 7
- 101001038300 Homo sapiens Protein ERGIC-53 Proteins 0.000 description 7
- 101001098802 Homo sapiens Protein disulfide-isomerase A3 Proteins 0.000 description 7
- 101000717424 Homo sapiens UV excision repair protein RAD23 homolog B Proteins 0.000 description 7
- 241000711504 Paramyxoviridae Species 0.000 description 7
- 239000012228 culture supernatant Substances 0.000 description 7
- 102000047985 human ZC3H12D Human genes 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- 239000013600 plasmid vector Substances 0.000 description 6
- 210000000605 viral structure Anatomy 0.000 description 6
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 5
- 101710157220 DNA primase large subunit Proteins 0.000 description 5
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 5
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 5
- 101710181008 P protein Proteins 0.000 description 5
- 101710177166 Phosphoprotein Proteins 0.000 description 5
- 101710173608 Protein ERGIC-53 Proteins 0.000 description 5
- 101710106224 Protein disulfide-isomerase A3 Proteins 0.000 description 5
- 239000004098 Tetracycline Substances 0.000 description 5
- 101710204645 UV excision repair protein RAD23 homolog B Proteins 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 229960002180 tetracycline Drugs 0.000 description 5
- 229930101283 tetracycline Natural products 0.000 description 5
- 235000019364 tetracycline Nutrition 0.000 description 5
- 150000003522 tetracyclines Chemical class 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 108020004705 Codon Proteins 0.000 description 4
- 241000711950 Filoviridae Species 0.000 description 4
- 101710133291 Hemagglutinin-neuraminidase Proteins 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 101710085938 Matrix protein Proteins 0.000 description 4
- 101710127721 Membrane protein Proteins 0.000 description 4
- 241000712045 Morbillivirus Species 0.000 description 4
- 102100034574 P protein Human genes 0.000 description 4
- 101710149951 Protein Tat Proteins 0.000 description 4
- 241000711931 Rhabdoviridae Species 0.000 description 4
- 230000037429 base substitution Effects 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 230000030609 dephosphorylation Effects 0.000 description 4
- 238000006209 dephosphorylation reaction Methods 0.000 description 4
- 238000006471 dimerization reaction Methods 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 239000012096 transfection reagent Substances 0.000 description 4
- 101710117545 C protein Proteins 0.000 description 3
- 101710177611 DNA polymerase II large subunit Proteins 0.000 description 3
- 101710184669 DNA polymerase II small subunit Proteins 0.000 description 3
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 3
- 101710141454 Nucleoprotein Proteins 0.000 description 3
- 108010079304 Picornavirus picornain 2A Proteins 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- FXYZDFSNBBOHTA-UHFFFAOYSA-N 2-[amino(morpholin-4-ium-4-ylidene)methyl]guanidine;chloride Chemical compound Cl.NC(N)=NC(=N)N1CCOCC1 FXYZDFSNBBOHTA-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000282552 Chlorocebus aethiops Species 0.000 description 2
- 101100072149 Drosophila melanogaster eIF2alpha gene Proteins 0.000 description 2
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 2
- 241001115402 Ebolavirus Species 0.000 description 2
- 101150008820 HN gene Proteins 0.000 description 2
- 241000724709 Hepatitis delta virus Species 0.000 description 2
- 241000282560 Macaca mulatta Species 0.000 description 2
- 241001115401 Marburgvirus Species 0.000 description 2
- 241000712079 Measles morbillivirus Species 0.000 description 2
- 241000711386 Mumps virus Species 0.000 description 2
- 241000713112 Orthobunyavirus Species 0.000 description 2
- 241000150452 Orthohantavirus Species 0.000 description 2
- 241000712464 Orthomyxoviridae Species 0.000 description 2
- 101150084044 P gene Proteins 0.000 description 2
- 241000150350 Peribunyaviridae Species 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 102000044126 RNA-Binding Proteins Human genes 0.000 description 2
- 108700020471 RNA-Binding Proteins Proteins 0.000 description 2
- 241000711798 Rabies lyssavirus Species 0.000 description 2
- 241001533467 Rubulavirus Species 0.000 description 2
- 101710137500 T7 RNA polymerase Proteins 0.000 description 2
- 101900001372 Vaccinia virus RNA-binding protein E3 Proteins 0.000 description 2
- 108700024019 Vaccinia virus pK3 Proteins 0.000 description 2
- 241000711970 Vesiculovirus Species 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 2
- HJUFTIJOISQSKQ-UHFFFAOYSA-N fenoxycarb Chemical compound C1=CC(OCCNC(=O)OCC)=CC=C1OC1=CC=CC=C1 HJUFTIJOISQSKQ-UHFFFAOYSA-N 0.000 description 2
- 108700008776 hepatitis C virus NS-5 Proteins 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 108700032552 influenza virus INS1 Proteins 0.000 description 2
- 108060004127 isopentenyl phosphate kinase Proteins 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000007758 minimum essential medium Substances 0.000 description 2
- 108091027963 non-coding RNA Proteins 0.000 description 2
- 102000042567 non-coding RNA Human genes 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 230000005727 virus proliferation Effects 0.000 description 2
- QNQZPJLBGRQFDD-ZMSORURPSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-[(1r)-1-hydroxyethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;sulfuric acid Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H]([C@@H](C)O)O2)N)[C@@H](N)C[C@H]1N QNQZPJLBGRQFDD-ZMSORURPSA-N 0.000 description 1
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
- 108020005065 3' Flanking Region Proteins 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 108020005029 5' Flanking Region Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 101150039392 CBL3 gene Proteins 0.000 description 1
- 101100244725 Caenorhabditis elegans pef-1 gene Proteins 0.000 description 1
- 101150058299 Cblc gene Proteins 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 102000000331 Double-stranded RNA-binding domains Human genes 0.000 description 1
- 108050008793 Double-stranded RNA-binding domains Proteins 0.000 description 1
- 101100118093 Drosophila melanogaster eEF1alpha2 gene Proteins 0.000 description 1
- 102100035275 E3 ubiquitin-protein ligase CBL-C Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004961 Furin Human genes 0.000 description 1
- 108090001126 Furin Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000037262 Hepatitis delta Diseases 0.000 description 1
- 101000974349 Homo sapiens Nuclear receptor coactivator 6 Proteins 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 101150118742 NP gene Proteins 0.000 description 1
- 239000012124 Opti-MEM Substances 0.000 description 1
- 102000005877 Peptide Initiation Factors Human genes 0.000 description 1
- 108010044843 Peptide Initiation Factors Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102100026965 RISC-loading complex subunit TARBP2 Human genes 0.000 description 1
- 102000017143 RNA Polymerase I Human genes 0.000 description 1
- 108010013845 RNA Polymerase I Proteins 0.000 description 1
- 241001113283 Respirovirus Species 0.000 description 1
- 241000251131 Sphyrna Species 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091027572 Twister ribozyme Proteins 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- -1 for example Proteins 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 108090001052 hairpin ribozyme Proteins 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000029570 hepatitis D virus infection Diseases 0.000 description 1
- GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 1
- 229940097277 hygromycin b Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 108091005981 phosphorylated proteins Proteins 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 102200148755 rs121909280 Human genes 0.000 description 1
- 102200066484 rs145437203 Human genes 0.000 description 1
- 102200069418 rs4453725 Human genes 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0684—Cells of the urinary tract or kidneys
- C12N5/0686—Kidney cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18421—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18451—Methods of production or purification of viral material
- C12N2760/18452—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
- C12N2760/18721—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
- C12N2760/18751—Methods of production or purification of viral material
- C12N2760/18752—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18811—Sendai virus
- C12N2760/18821—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18811—Sendai virus
- C12N2760/18841—Use of virus, viral particle or viral elements as a vector
- C12N2760/18843—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18811—Sendai virus
- C12N2760/18851—Methods of production or purification of viral material
- C12N2760/18852—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20251—Methods of production or purification of viral material
- C12N2760/20252—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025014649A JP2025069294A (ja) | 2021-06-30 | 2025-01-31 | マイナス鎖ｒｎａウイルスベクターの製造方法および製造されたマイナス鎖ｒｎａウイルスベクター |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021108757 | 2021-06-30 | ||
| JP2021108757 | 2021-06-30 | ||
| PCT/JP2022/025983 WO2023277069A1 (ja) | 2021-06-30 | 2022-06-29 | マイナス鎖ｒｎａウイルスベクターの製造方法および製造されたマイナス鎖ｒｎａウイルスベクター |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025014649A Division JP2025069294A (ja) | 2021-06-30 | 2025-01-31 | マイナス鎖ｒｎａウイルスベクターの製造方法および製造されたマイナス鎖ｒｎａウイルスベクター |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2023277069A1 JPWO2023277069A1 (enrdf_load_stackoverflow) | 2023-01-05 |
| JP7633725B2 true JP7633725B2 (ja) | 2025-02-20 |
Family
ID=84691835
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023532022A Active JP7633725B2 (ja) | 2021-06-30 | 2022-06-29 | マイナス鎖ｒｎａウイルスベクターの製造方法および製造されたマイナス鎖ｒｎａウイルスベクター |
| JP2024530281A Pending JPWO2024004235A1 (enrdf_load_stackoverflow) | 2021-06-30 | 2022-12-26 | |
| JP2025014649A Pending JP2025069294A (ja) | 2021-06-30 | 2025-01-31 | マイナス鎖ｒｎａウイルスベクターの製造方法および製造されたマイナス鎖ｒｎａウイルスベクター |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024530281A Pending JPWO2024004235A1 (enrdf_load_stackoverflow) | 2021-06-30 | 2022-12-26 | |
| JP2025014649A Pending JP2025069294A (ja) | 2021-06-30 | 2025-01-31 | マイナス鎖ｒｎａウイルスベクターの製造方法および製造されたマイナス鎖ｒｎａウイルスベクター |
Country Status (8)
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001514519A (ja) | 1997-03-12 | 2001-09-11 | ヴァイロジェネティクス コーポレイション | 発現が増強されたベクターならびにそれらの作出方法および用途 |
| JP2001514518A (ja) | 1997-03-12 | 2001-09-11 | ヴァイロジェネティクス コーポレイション | 発現の向上したベクター並びにその製造および使用方法 |
| WO2005071092A1 (ja) | 2004-01-22 | 2005-08-04 | Dnavec Research Inc. | サイトメガロウイルスエンハンサーおよびニワトリβ-アクチンプロモーターを含むハイブリッドプロモーターを利用したマイナス鎖RNAウイルスベクターの製造方法 |
| JP2005534326A (ja) | 2002-08-07 | 2005-11-17 | バヴァリアン・ノルディック・アクティーゼルスカブ | アビポックスウイルスの力価を増加させるためのワクシニアウイルス宿主域遺伝子 |
| JP2015534826A (ja) | 2012-11-09 | 2015-12-07 | バイオエヌテック アーゲーＢｉｏＮＴｅｃｈ ＡＧ | 細胞のｒｎａ発現方法 |
| JP2020534810A (ja) | 2017-09-13 | 2020-12-03 | バイオエヌテック エールエヌアー ファーマシューティカルズ ゲーエムベーハーＢｉｏｎｔｅｃｈ Ｒｎａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｇｍｂｈ | 細胞におけるｒｎａ発現を増強する方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5585237A (en) | 1993-10-25 | 1996-12-17 | Creative Biomolecules, Inc. | Methods and compositions for high protein production from recombinant DNA |
| US20050130123A1 (en) | 2001-09-18 | 2005-06-16 | Makoto Inoue | Methods of examining (-) strand rna virus vectors having lowered ability to form grains and method of constructing the same |
| EP1715048A4 (en) | 2004-01-22 | 2007-02-07 | Dnavec Research Inc | PROCESS FOR PRODUCING A VIRAL VECTOR |
| WO2020117003A1 (ko) * | 2018-12-06 | 2020-06-11 | 국립암센터 | Nc886을 포함하는 암살상 바이러스 활성 증진 또는 생산 증진용 조성물 |
-
2022
- 2022-06-29 CN CN202280045809.9A patent/CN117651774A/zh active Pending
- 2022-06-29 CA CA3225564A patent/CA3225564A1/en active Pending
- 2022-06-29 WO PCT/JP2022/025983 patent/WO2023277069A1/ja active Application Filing
- 2022-06-29 US US18/575,633 patent/US20240309335A1/en active Pending
- 2022-06-29 JP JP2023532022A patent/JP7633725B2/ja active Active
- 2022-06-29 EP EP22833215.1A patent/EP4365298A4/en active Pending
- 2022-06-29 AU AU2022302552A patent/AU2022302552A1/en active Pending
- 2022-12-26 TW TW111149926A patent/TW202400795A/zh unknown
- 2022-12-26 AU AU2022467248A patent/AU2022467248A1/en active Pending
- 2022-12-26 WO PCT/JP2022/047801 patent/WO2024004235A1/ja not_active Application Discontinuation
- 2022-12-26 CN CN202280097604.5A patent/CN119384508A/zh active Pending
- 2022-12-26 JP JP2024530281A patent/JPWO2024004235A1/ja active Pending
- 2022-12-26 EP EP22949508.0A patent/EP4549578A1/en not_active Withdrawn
-
2025
- 2025-01-31 JP JP2025014649A patent/JP2025069294A/ja active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001514519A (ja) | 1997-03-12 | 2001-09-11 | ヴァイロジェネティクス コーポレイション | 発現が増強されたベクターならびにそれらの作出方法および用途 |
| JP2001514518A (ja) | 1997-03-12 | 2001-09-11 | ヴァイロジェネティクス コーポレイション | 発現の向上したベクター並びにその製造および使用方法 |
| JP2005534326A (ja) | 2002-08-07 | 2005-11-17 | バヴァリアン・ノルディック・アクティーゼルスカブ | アビポックスウイルスの力価を増加させるためのワクシニアウイルス宿主域遺伝子 |
| WO2005071092A1 (ja) | 2004-01-22 | 2005-08-04 | Dnavec Research Inc. | サイトメガロウイルスエンハンサーおよびニワトリβ-アクチンプロモーターを含むハイブリッドプロモーターを利用したマイナス鎖RNAウイルスベクターの製造方法 |
| JP2015534826A (ja) | 2012-11-09 | 2015-12-07 | バイオエヌテック アーゲーＢｉｏＮＴｅｃｈ ＡＧ | 細胞のｒｎａ発現方法 |
| JP2020534810A (ja) | 2017-09-13 | 2020-12-03 | バイオエヌテック エールエヌアー ファーマシューティカルズ ゲーエムベーハーＢｉｏｎｔｅｃｈ Ｒｎａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｇｍｂｈ | 細胞におけるｒｎａ発現を増強する方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN117651774A (zh) | 2024-03-05 |
| CA3225564A1 (en) | 2023-01-05 |
| JPWO2024004235A1 (enrdf_load_stackoverflow) | 2024-01-04 |
| WO2024004235A1 (ja) | 2024-01-04 |
| US20240309335A1 (en) | 2024-09-19 |
| JP2025069294A (ja) | 2025-04-30 |
| AU2022467248A1 (en) | 2025-01-23 |
| EP4365298A4 (en) | 2025-09-10 |
| CN119384508A (zh) | 2025-01-28 |
| AU2022302552A1 (en) | 2024-02-08 |
| WO2023277069A1 (ja) | 2023-01-05 |
| TW202400795A (zh) | 2024-01-01 |
| EP4365298A1 (en) | 2024-05-08 |
| JPWO2023277069A1 (enrdf_load_stackoverflow) | 2023-01-05 |
| EP4549578A1 (en) | 2025-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101279677B1 (ko) | 사이토메갈로바이러스 인핸서 및 닭 β액틴 프로모터를 포함하는 하이브리드 프로모터를 이용한 마이너스 가닥 ＲＮＡ 바이러스 벡터의 제조방법 | |
| Billeter et al. | Reverse genetics of measles virus and resulting multivalent recombinant vaccines: applications of recombinant measles viruses | |
| CN109312366B (zh) | 用于肿瘤溶瘤治疗的vsv/ndv杂合病毒 | |
| JP4936482B2 (ja) | 改良された持続感染型センダイウイルスベクター | |
| WO1997016538A1 (fr) | Vecteur de virus d'arn a brin negatif possedant une activite de replication autonome | |
| JP6927883B2 (ja) | 改良されたパラミクソウイルスベクター | |
| KR20090114431A (ko) | 약독화 마이너스 가닥 ｒｎａ 바이러스 | |
| Marschalek et al. | The importance of being short: the role of rabies virus phosphoprotein isoforms assessed by differential IRES translation initiation | |
| JP7633725B2 (ja) | マイナス鎖ｒｎａウイルスベクターの製造方法および製造されたマイナス鎖ｒｎａウイルスベクター | |
| JP2025081483A (ja) | 温度感受性のマイナス鎖ｒｎａウイルスまたはウイルスベクターおよびそのｒｎａゲノム | |
| Wyss et al. | Efficient recovery of attenuated canine distemper virus from cDNA | |
| Sauder et al. | Presence of lysine at aa 335 of the hemagglutinin-neuraminidase protein of mumps virus vaccine strain Urabe AM9 is not a requirement for neurovirulence | |
| JP2013524798A (ja) | 腫瘍性疾患を治療するための遺伝子組み換えパラミクソウイルス | |
| Alizadeh et al. | Generation of recombinant measles virus containing the wild-type P gene to improve its oncolytic efficiency | |
| WO2024195811A1 (ja) | 温度感受性のマイナス鎖ｒｎａウイルスまたはウイルスベクターおよびそのｒｎａゲノム | |
| JP2022537268A (ja) | Ｒｎａウイルスの複製と遺伝子発現を制御する新たな仕組み | |
| Theriault | The role of reverse genetics systems in the study of filovirus pathogenicity | |
| HK1094898A (en) | Methods for producing minus-strand rna viral vectors using hybrid promoter comprising cytomegalovirus enhancer and chicken beta-actin promoter |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240924 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20240924 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20241008 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241106 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20241119 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241219 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20250107 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20250131 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7633725 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |